Symbols / SKYE Stock $0.77 +6.04% Skye Bioscience, Inc.
SKYE (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteSkye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-30 | init | HC Wainwright & Co. | — → Buy | $20 |
| 2025-08-15 | init | Evercore ISI Group | — → Outperform | $10 |
| 2025-06-24 | reit | JMP Securities | Market Outperform → Market Outperform | $15 |
| 2025-03-21 | main | Craig-Hallum | Buy → Buy | $14 |
| 2025-03-21 | reit | Citizens Capital Markets | Market Outperform → Market Outperform | $15 |
| 2025-02-28 | init | William Blair | — → Outperform | — |
| 2024-09-30 | init | Scotiabank | — → Sector Outperform | $20 |
| 2024-09-20 | reit | Piper Sandler | Overweight → Overweight | $20 |
| 2024-09-20 | reit | Cantor Fitzgerald | Overweight → Overweight | $14 |
| 2024-09-10 | init | JMP Securities | — → Market Outperform | $15 |
| 2024-09-09 | reit | Cantor Fitzgerald | Overweight → Overweight | $14 |
| 2024-09-06 | reit | Cantor Fitzgerald | Overweight → Overweight | $14 |
| 2024-08-27 | reit | Cantor Fitzgerald | Overweight → Overweight | $14 |
| 2024-07-09 | init | Craig-Hallum | — → Buy | $18 |
| 2024-07-01 | reit | Cantor Fitzgerald | Overweight → Overweight | $14 |
| 2024-06-18 | reit | Cantor Fitzgerald | Overweight → Overweight | $14 |
| 2024-06-17 | reit | Cantor Fitzgerald | Overweight → Overweight | $14 |
| 2024-05-23 | init | Cantor Fitzgerald | — → Overweight | $21 |
| 2024-04-12 | init | Oppenheimer | — → Outperform | $25 |
| 2024-03-14 | reit | Piper Sandler | Overweight → Overweight | $20 |
- Obesity drug trial sees no serious side effects as dose moves higher - Stock Titan Wed, 20 May 2026 11
- Skye Bioscience gets approval to open second cohort in study By Investing.com - Investing.com Nigeria Wed, 20 May 2026 15
- SKYE Stock Chart | SKYE BIOSCIENCE INC (NASDAQ:SKYE) - ChartMill Fri, 15 May 2026 07
- Skye’s shares crash down to earth on Phase II obesity loss - Clinical Trials Arena ue, 07 Oct 2025 07
- SKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II Goal - Yahoo Finance ue, 07 Oct 2025 07
- Skye Bioscience Faces Nasdaq Compliance Risk Over Equity - TipRanks Fri, 15 May 2026 21
- Skye Bioscience Initiates CBeyond™ Expansion Study (Part C) with Planned Review on May 18, 2026 - Quiver Quantitative ue, 12 May 2026 17
- Skye shares crash as obesity drug falls short in key study - BioPharma Dive Mon, 06 Oct 2025 07
- [8-K] Skye Bioscience, Inc. Reports Material Event - Stock Titan Fri, 15 May 2026 20
- Why Skye Bioscience (SKYE) Is Down 51.0% After Releasing Phase 2a Nimacimab Trial Results and What's Next - Yahoo Finance ue, 07 Oct 2025 07
- Skye obesity drug combo saw 22.3% weight loss at 52 weeks - Stock Titan ue, 12 May 2026 17
- Skye weight-loss trial combo hits 22% mean loss at 52 weeks - Stock Titan Mon, 11 May 2026 07
- Skye Bioscience (SKYE) CFO John P. Sharp files initial Form 3 - Stock Titan ue, 28 Apr 2026 07
- Clinical-stage obesity biotech Skye sets March 10 results call - Stock Titan hu, 05 Mar 2026 08
- Skye obesity drug combo shows 22.3% loss, over 50% less regain - Stock Titan ue, 10 Mar 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
58.16
+59.67%
|
36.43
+166.44%
|
13.67
+12.93%
|
12.11
|
| Research And Development |
|
42.36
+126.51%
|
18.70
+221.36%
|
5.82
-3.20%
|
6.01
|
| Selling General And Administration |
|
15.80
-10.85%
|
17.73
+125.74%
|
7.85
+28.84%
|
6.09
|
| General And Administrative Expense |
|
15.80
-10.85%
|
17.73
+125.74%
|
7.85
+28.84%
|
6.09
|
| Other Gand A |
|
15.80
-10.85%
|
17.73
+125.74%
|
7.85
+28.84%
|
6.09
|
| Total Expenses |
|
58.16
+59.67%
|
36.43
+166.44%
|
13.67
+12.93%
|
12.11
|
| Operating Income |
|
-58.16
-59.67%
|
-36.43
-166.44%
|
-13.67
-12.93%
|
-12.11
|
| Total Operating Income As Reported |
|
-58.16
-92.64%
|
-30.19
+13.08%
|
-34.74
-89.69%
|
-18.31
|
| EBITDA |
|
-55.20
-118.25%
|
-25.29
+30.94%
|
-36.62
-95.87%
|
-18.70
|
| Normalized EBITDA |
|
-55.56
-68.95%
|
-32.88
-121.59%
|
-14.84
-22.70%
|
-12.09
|
| Reconciled Depreciation |
|
0.72
+142.22%
|
0.30
+140.35%
|
0.12
+8.05%
|
0.11
|
| EBIT |
|
-55.92
-118.53%
|
-25.59
+30.36%
|
-36.74
-95.33%
|
-18.81
|
| Total Unusual Items |
|
0.36
-95.25%
|
7.59
+134.86%
|
-21.78
-229.89%
|
-6.60
|
| Total Unusual Items Excluding Goodwill |
|
0.36
-95.25%
|
7.59
+134.86%
|
-21.78
-229.89%
|
-6.60
|
| Special Income Charges |
|
0.36
-95.25%
|
7.59
+134.86%
|
-21.78
-226.93%
|
-6.66
|
| Other Special Charges |
|
—
|
-6.23
-129.60%
|
21.06
+239.44%
|
6.21
|
| Restructuring And Mergern Acquisition |
|
—
|
—
|
0.41
-10.33%
|
0.46
|
| Write Off |
|
—
|
—
|
—
|
0.46
|
| Net Income |
|
-55.92
-110.50%
|
-26.57
+29.43%
|
-37.64
-93.23%
|
-19.48
|
| Pretax Income |
|
-55.92
-110.56%
|
-26.56
+29.45%
|
-37.64
-93.28%
|
-19.47
|
| Net Non Operating Interest Income Expense |
|
1.88
-17.35%
|
2.28
+382.71%
|
-0.81
-5.21%
|
-0.77
|
| Interest Expense Non Operating |
|
0.00
-100.00%
|
0.97
+7.85%
|
0.90
+35.17%
|
0.66
|
| Net Interest Income |
|
1.88
-17.35%
|
2.28
+382.71%
|
-0.81
-5.21%
|
-0.77
|
| Interest Expense |
|
0.00
-100.00%
|
0.97
+7.85%
|
0.90
+35.17%
|
0.66
|
| Interest Income Non Operating |
|
1.88
-42.27%
|
3.26
+3164.36%
|
0.10
+425.87%
|
0.02
|
| Interest Income |
|
1.88
-42.27%
|
3.26
+3164.36%
|
0.10
+425.87%
|
0.02
|
| Other Income Expense |
|
0.36
-95.25%
|
7.59
+132.77%
|
-23.16
-250.84%
|
-6.60
|
| Other Non Operating Income Expenses |
|
-0.00
+77.18%
|
-0.00
+99.84%
|
-1.38
|
—
|
| Gain On Sale Of Security |
|
—
|
—
|
0.00
-99.99%
|
0.06
|
| Gain On Sale Of Business |
|
—
|
0.00
+100.00%
|
-0.41
+10.33%
|
-0.46
|
| Tax Provision |
|
0.01
-46.38%
|
0.01
+179.75%
|
0.00
-46.60%
|
0.01
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.08
-95.25%
|
1.59
+134.86%
|
-4.57
-229.89%
|
-1.39
|
| Net Income Including Noncontrolling Interests |
|
-55.92
-110.50%
|
-26.57
+29.43%
|
-37.64
-93.23%
|
-19.48
|
| Net Income From Continuing Operation Net Minority Interest |
|
-55.92
-110.50%
|
-26.57
+29.43%
|
-37.64
-93.23%
|
-19.48
|
| Net Income From Continuing And Discontinued Operation |
|
-55.92
-110.50%
|
-26.57
+29.43%
|
-37.64
-93.23%
|
-19.48
|
| Net Income Continuous Operations |
|
-55.92
-110.50%
|
-26.57
+29.43%
|
-37.64
-93.23%
|
-19.48
|
| Normalized Income |
|
-56.21
-72.60%
|
-32.57
-59.33%
|
-20.44
-43.27%
|
-14.27
|
| Net Income Common Stockholders |
|
-55.92
-110.50%
|
-26.57
+29.43%
|
-37.64
-93.23%
|
-19.48
|
| Diluted EPS |
|
-1.41
-93.15%
|
-0.73
+86.41%
|
-5.37
+38.77%
|
-8.77
|
| Basic EPS |
|
-1.41
-93.15%
|
-0.73
+86.41%
|
-5.37
+38.77%
|
-8.77
|
| Basic Average Shares |
|
39.66
+8.70%
|
36.49
+420.79%
|
7.01
+215.43%
|
2.22
|
| Diluted Average Shares |
|
39.66
+8.70%
|
36.49
+420.79%
|
7.01
+215.43%
|
2.22
|
| Diluted NI Availto Com Stockholders |
|
-55.92
-110.50%
|
-26.57
+29.43%
|
-37.64
-93.23%
|
-19.48
|
| Gain On Sale Of PPE |
|
0.36
-73.44%
|
1.36
+542.36%
|
-0.31
|
0.00
|
| Total Other Finance Cost |
|
—
|
0.02
+81.57%
|
0.01
-92.55%
|
0.12
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
28.31
-61.09%
|
72.76
+509.39%
|
11.94
+31.05%
|
9.11
|
| Current Assets |
|
27.09
-61.75%
|
70.83
+507.92%
|
11.65
+30.27%
|
8.94
|
| Cash Cash Equivalents And Short Term Investments |
|
25.74
-62.38%
|
68.42
+5345.15%
|
1.26
+0.96%
|
1.24
|
| Cash And Cash Equivalents |
|
5.88
-91.40%
|
68.42
+5345.15%
|
1.26
+0.96%
|
1.24
|
| Cash Financial |
|
—
|
—
|
1.26
+0.96%
|
1.24
|
| Other Short Term Investments |
|
19.85
|
0.00
|
—
|
—
|
| Receivables |
|
0.01
+106.79%
|
0.01
-96.80%
|
0.16
+113.49%
|
0.07
|
| Taxes Receivable |
|
0.01
+106.79%
|
0.01
-96.80%
|
0.16
+113.49%
|
0.07
|
| Prepaid Assets |
|
1.33
-39.40%
|
2.20
+267.95%
|
0.60
-32.25%
|
0.88
|
| Restricted Cash |
|
—
|
0.00
-100.00%
|
9.08
+198157.69%
|
0.00
|
| Assets Held For Sale Current |
|
—
|
—
|
0.00
-100.00%
|
6.43
|
| Other Current Assets |
|
0.01
-93.35%
|
0.21
-62.88%
|
0.56
+82.39%
|
0.31
|
| Total Non Current Assets |
|
1.22
-37.03%
|
1.94
+568.76%
|
0.29
+73.03%
|
0.17
|
| Net PPE |
|
1.17
-38.09%
|
1.88
+569.35%
|
0.28
+76.84%
|
0.16
|
| Gross PPE |
|
1.94
-8.36%
|
2.12
+461.76%
|
0.38
+136.85%
|
0.16
|
| Accumulated Depreciation |
|
-0.77
-231.31%
|
-0.23
-144.69%
|
-0.10
|
—
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
—
|
—
|
0.04
-50.74%
|
0.09
|
| Machinery Furniture Equipment |
|
1.65
+0.38%
|
1.64
+1216.45%
|
0.12
|
—
|
| Other Properties |
|
0.27
-40.73%
|
0.45
+89.03%
|
0.24
+234.29%
|
0.07
|
| Leases |
|
0.02
+0.00%
|
0.02
+71.41%
|
0.01
|
—
|
| Other Non Current Assets |
|
0.05
+0.00%
|
0.05
+548.81%
|
0.01
+0.00%
|
0.01
|
| Total Liabilities Net Minority Interest |
|
8.29
+79.73%
|
4.61
-67.23%
|
14.07
+16.12%
|
12.12
|
| Current Liabilities |
|
8.21
+89.11%
|
4.34
-68.79%
|
13.90
+14.70%
|
12.12
|
| Payables And Accrued Expenses |
|
5.38
+49.19%
|
3.61
-57.50%
|
8.49
+219.82%
|
2.65
|
| Payables |
|
2.03
+257.21%
|
0.57
-40.50%
|
0.96
-49.40%
|
1.89
|
| Accounts Payable |
|
2.03
+257.21%
|
0.57
-40.50%
|
0.96
-46.70%
|
1.79
|
| Other Payable |
|
—
|
—
|
—
|
0.06
|
| Current Accrued Expenses |
|
3.35
+10.22%
|
3.04
-59.66%
|
7.53
+886.97%
|
0.76
|
| Current Debt And Capital Lease Obligation |
|
0.19
+3.96%
|
0.18
-95.89%
|
4.44
+124.16%
|
1.98
|
| Current Debt |
|
—
|
—
|
4.37
+129.64%
|
1.90
|
| Other Current Borrowings |
|
—
|
—
|
4.37
+129.64%
|
1.90
|
| Current Capital Lease Obligation |
|
0.19
+3.96%
|
0.18
+153.24%
|
0.07
-8.47%
|
0.08
|
| Other Current Liabilities |
|
2.63
+379.64%
|
0.55
-43.36%
|
0.97
-87.04%
|
7.48
|
| Total Non Current Liabilities Net Minority Interest |
|
0.08
-69.25%
|
0.27
+59.53%
|
0.17
|
0.00
|
| Long Term Debt And Capital Lease Obligation |
|
0.08
-69.25%
|
0.27
+59.53%
|
0.17
|
0.00
|
| Long Term Capital Lease Obligation |
|
0.08
-69.25%
|
0.27
+59.53%
|
0.17
|
0.00
|
| Stockholders Equity |
|
20.02
-70.62%
|
68.15
+3296.88%
|
-2.13
+29.13%
|
-3.01
|
| Common Stock Equity |
|
20.02
-70.62%
|
68.15
+3296.88%
|
-2.13
+29.13%
|
-3.01
|
| Capital Stock |
|
0.03
+7.76%
|
0.03
+150.83%
|
0.01
+237.96%
|
0.00
|
| Common Stock |
|
0.03
+7.76%
|
0.03
+150.83%
|
0.01
+237.96%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
33.38
+7.76%
|
30.97
+150.82%
|
12.35
+237.95%
|
3.65
|
| Ordinary Shares Number |
|
33.38
+7.76%
|
30.97
+150.82%
|
12.35
+237.95%
|
3.65
|
| Additional Paid In Capital |
|
206.87
+3.92%
|
199.07
+94.71%
|
102.24
+60.43%
|
63.73
|
| Retained Earnings |
|
-186.87
-42.71%
|
-130.95
-25.45%
|
-104.38
-56.41%
|
-66.74
|
| Total Equity Gross Minority Interest |
|
20.02
-70.62%
|
68.15
+3296.88%
|
-2.13
+29.13%
|
-3.01
|
| Total Capitalization |
|
20.02
-70.62%
|
68.15
+3296.88%
|
-2.13
+29.13%
|
-3.01
|
| Working Capital |
|
18.89
-71.59%
|
66.49
+3054.83%
|
-2.25
+29.14%
|
-3.18
|
| Invested Capital |
|
20.02
-70.62%
|
68.15
+2942.24%
|
2.24
+302.87%
|
-1.10
|
| Total Debt |
|
0.27
-39.94%
|
0.46
-90.13%
|
4.62
+132.80%
|
1.98
|
| Net Debt |
|
—
|
—
|
3.12
+372.55%
|
0.66
|
| Capital Lease Obligations |
|
0.27
-39.94%
|
0.46
+87.28%
|
0.24
+209.11%
|
0.08
|
| Net Tangible Assets |
|
20.02
-70.62%
|
68.15
+3296.88%
|
-2.13
+29.13%
|
-3.01
|
| Tangible Book Value |
|
20.02
-70.62%
|
68.15
+3296.88%
|
-2.13
+29.13%
|
-3.01
|
| Dueto Related Parties Current |
|
—
|
—
|
0.00
-100.00%
|
0.10
|
| Interest Payable |
|
—
|
0.00
-100.00%
|
0.36
+2181.38%
|
0.02
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-43.06
-70.63%
|
-25.24
-80.89%
|
-13.95
-9.48%
|
-12.74
|
| Cash Flow From Continuing Operating Activities |
|
-43.06
-70.63%
|
-25.24
-80.89%
|
-13.95
-9.48%
|
-12.74
|
| Net Income From Continuing Operations |
|
-55.92
-110.50%
|
-26.57
+29.43%
|
-37.64
-93.23%
|
-19.48
|
| Depreciation Amortization Depletion |
|
0.72
+142.22%
|
0.30
+140.35%
|
0.12
+8.05%
|
0.11
|
| Depreciation And Amortization |
|
0.72
+142.22%
|
0.30
+140.35%
|
0.12
+8.05%
|
0.11
|
| Other Non Cash Items |
|
—
|
-3.64
-330.50%
|
1.58
-76.86%
|
6.82
|
| Stock Based Compensation |
|
7.77
-6.61%
|
8.32
+742.27%
|
0.99
+56.99%
|
0.63
|
| Asset Impairment Charge |
|
0.00
-100.00%
|
0.33
|
0.00
|
—
|
| Operating Gains Losses |
|
-0.36
+73.23%
|
-1.35
-106.28%
|
21.47
+36050.49%
|
-0.06
|
| Gain Loss On Investment Securities |
|
—
|
—
|
-0.00
+99.99%
|
-0.06
|
| Net Foreign Currency Exchange Gain Loss |
|
—
|
0.00
+100.00%
|
-0.05
|
0.00
|
| Gain Loss On Sale Of PPE |
|
—
|
0.00
-100.00%
|
21.22
|
0.00
|
| Change In Working Capital |
|
4.73
+280.01%
|
-2.63
-460.14%
|
-0.47
+38.40%
|
-0.76
|
| Change In Prepaid Assets |
|
-0.30
-3832.60%
|
-0.01
-100.97%
|
0.80
+26929.69%
|
-0.00
|
| Change In Payables And Accrued Expense |
|
1.55
+314.94%
|
-0.72
-556.68%
|
-0.11
-111.52%
|
0.95
|
| Change In Accrued Expense |
|
0.16
+215.06%
|
-0.13
-122.81%
|
0.59
+283.58%
|
0.15
|
| Change In Payable |
|
1.40
+337.91%
|
-0.59
+16.36%
|
-0.70
-187.69%
|
0.80
|
| Change In Account Payable |
|
1.40
+337.91%
|
-0.59
+16.36%
|
-0.70
-187.69%
|
0.80
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
—
|
| Change In Other Current Assets |
|
1.36
+192.93%
|
-1.46
-198.87%
|
-0.49
-532.91%
|
0.11
|
| Change In Other Current Liabilities |
|
2.13
+584.68%
|
-0.44
+34.10%
|
-0.67
+63.53%
|
-1.83
|
| Investing Cash Flow |
|
-19.50
-7839.37%
|
-0.25
-103.72%
|
6.60
+26.50%
|
5.21
|
| Cash Flow From Continuing Investing Activities |
|
-19.50
-7839.37%
|
-0.25
-103.72%
|
6.60
+26.50%
|
5.21
|
| Net PPE Purchase And Sale |
|
0.35
+244.31%
|
-0.25
-104.45%
|
5.52
+19771.12%
|
-0.03
|
| Purchase Of PPE |
|
-0.01
+99.61%
|
-1.60
-12681.09%
|
-0.01
+55.27%
|
-0.03
|
| Sale Of PPE |
|
0.36
-73.44%
|
1.36
-75.45%
|
5.53
|
0.00
|
| Capital Expenditure |
|
-0.01
+99.61%
|
-1.60
-12681.09%
|
-0.01
+55.27%
|
-0.03
|
| Net Investment Purchase And Sale |
|
-19.85
|
0.00
|
—
|
—
|
| Purchase Of Investment |
|
-19.85
|
0.00
|
—
|
—
|
| Net Other Investing Changes |
|
—
|
—
|
1.08
-79.46%
|
5.24
|
| Financing Cash Flow |
|
0.03
-99.96%
|
83.56
+408.18%
|
16.44
+7975.36%
|
-0.21
|
| Cash Flow From Continuing Financing Activities |
|
0.03
-99.96%
|
83.56
+408.18%
|
16.44
+7975.36%
|
-0.21
|
| Net Issuance Payments Of Debt |
|
—
|
0.00
-100.00%
|
4.71
+2336.82%
|
-0.21
|
| Issuance Of Debt |
|
—
|
0.00
-100.00%
|
4.97
+630.46%
|
0.68
|
| Repayment Of Debt |
|
—
|
0.00
+100.00%
|
-0.26
+70.92%
|
-0.89
|
| Long Term Debt Issuance |
|
—
|
—
|
0.00
-100.00%
|
0.68
|
| Long Term Debt Payments |
|
—
|
0.00
+100.00%
|
-0.26
+70.92%
|
-0.89
|
| Net Long Term Debt Issuance |
|
—
|
0.00
+100.00%
|
-0.26
-23.05%
|
-0.21
|
| Short Term Debt Issuance |
|
—
|
0.00
-100.00%
|
4.97
|
0.00
|
| Short Term Debt Payments |
|
—
|
—
|
-0.01
+99.02%
|
-0.62
|
| Net Short Term Debt Issuance |
|
—
|
0.00
-100.00%
|
4.97
|
0.00
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
83.56
+612.03%
|
11.73
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.03
+426.36%
|
0.01
|
0.00
-100.00%
|
0.00
|
| Net Other Financing Charges |
|
—
|
—
|
-0.01
|
—
|
| Changes In Cash |
|
-62.53
-207.67%
|
58.08
+539.11%
|
9.09
+217.43%
|
-7.74
|
| Beginning Cash Position |
|
68.42
+561.88%
|
10.34
+727.52%
|
1.25
-86.10%
|
8.99
|
| End Cash Position |
|
5.88
-91.40%
|
68.42
+561.88%
|
10.34
+727.52%
|
1.25
|
| Free Cash Flow |
|
-43.07
-60.46%
|
-26.84
-92.21%
|
-13.96
-9.34%
|
-12.77
|
| Interest Paid Supplemental Data |
|
0.00
-100.00%
|
0.43
+118.47%
|
0.20
-40.53%
|
0.33
|
| Income Tax Paid Supplemental Data |
|
0.01
+3.85%
|
0.01
+44.44%
|
0.00
-46.60%
|
0.01
|
| Change In Interest Payable |
|
0.00
+100.00%
|
-0.36
-200.00%
|
0.36
+326.77%
|
-0.16
|
| Common Stock Issuance |
|
0.00
-100.00%
|
83.56
+612.03%
|
11.73
|
0.00
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
83.56
+612.03%
|
11.73
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-05-15 View
- 10-Q2026-05-11 View
- 8-K2026-04-03 View
- 42026-04-02 View
- 42026-04-02 View
- 42026-04-02 View
- 42026-04-02 View
- 42026-04-02 View
- 42026-04-02 View
- 42026-04-02 View
- 42026-04-02 View
- 8-K2026-03-19 View
- 8-K2026-03-10 View
- 10-K2026-03-10 View
- 8-K2026-02-20 View
- 42026-02-09 View
- 42026-02-09 View
- 42026-02-09 View
- 42026-02-09 View
- 42026-02-09 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|